A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
Neuroendocrine Neoplasm
Interventions
DRUG

PM8002

IV infusion

DRUG

FOLFIRI

IV infusion

Trial Locations (13)

Unknown

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Fujian Province Cancer Hospital, Fuzhou

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Jingzhou First People's Hospital, Jingzhou

RECRUITING

Union Hospital Tongji Medical College of Hust, Wuhan

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

The Central Hospital of Yongzhou, Yongzhou

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

RECRUITING

Shandong Cancer Hospital, Jinan

RECRUITING

Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University), Kunming

RECRUITING

Chinese PLA General Hospital, Beijing

RECRUITING

ZhongShan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biotheus Inc.

INDUSTRY